North Carolina is currently home to 2666 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Facial Analysis to Classify Difficult Intubation
NCT01612949
Recruiting
The aim of this project is to develop a computer algorithm that can accurately predict how easy or difficult it is to intubate a patient based upon digital photographs from three different perspectives. Such an application can provide a consistent, quantitative measure of intubation difficulty by analyzing facial features in captured photographs - features which have previously been shown to correlate with how easy or how hard it would be to perform the intubation procedure. This is in contrast... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/21/2025
Locations: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Difficult Intubation
Register for Updates
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT05005975
Recruiting
To evaluate the long-term safety and tolerability of oral dersimelagon.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/20/2025
Locations: Wake Forest University Baptist Health, Winston-Salem, North Carolina
Conditions: EPP, XLP
Register for Updates
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NCT06395285
Recruiting
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2025
Locations: Duke Eye Center - Duke University Hospital, Durham, North Carolina
Conditions: ROSAH
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Atrium Health Sanger Heart and Vascular Institute, Charlotte, North Carolina
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
A Study of NE3107 in Early Parkinson's
NCT06757010
Recruiting
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants ha... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
04/18/2025
Locations: Science 37 (Nationwide Site), Morrisville, North Carolina
Conditions: Parkinsons Disease (PD)
Register for Updates
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NCT06404112
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: All sites listed under NCT06404086, Durham, North Carolina
Conditions: Long COVID, Long COVID-19, Sleep Disturbance
Register for Updates
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06404099
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: All sites listed under NCT06404086, Durham, North Carolina
Conditions: Long COVID, Long COVID-19, Hypersomnia
Register for Updates
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342
Recruiting
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subj... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Magnolia Clinical Research, Cary, North Carolina
Conditions: Major Depressive Disorder
Register for Updates
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
NCT06228053
Recruiting
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Duke University, Durham, North Carolina
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
NCT06043817
Recruiting
Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Levine Cancer Institute - Charlotte, Charlotte, North Carolina
Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Register for Updates
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Medication Management, LLC, Greensboro, North Carolina
Conditions: Chronic Heart Failure
Register for Updates